Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of a China-made recombinant COVID-19 vaccine (Sf9 cells) in healthy adults
jRCT2051210057Phase 2Completed
- Sponsor
- WestVac Biopharma
- Start
- Aug 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by WestVac Biopharma. Primary endpoint: Incidence of adverse reactions during 7 days after each dose. Started Aug 2021; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051210057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210057.